India · Delayed Price · Currency is INR Mankind Pharma Statistics
Total Valuation
Mankind Pharma has a market cap or net worth of INR 850.58 billion. The enterprise value is 901.71 billion.
| Market Cap | 850.58B |
| Enterprise Value | 901.71B |
Important Dates
The last earnings date was Tuesday, February 3, 2026.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Aug 8, 2025 |
Share Statistics
| Current Share Class | 412.81M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.76% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 57.71% |
| Owned by Institutions (%) | 20.93% |
| Float | 106.31M |
Valuation Ratios
The trailing PE ratio is 47.80 and the forward PE ratio is 36.51.
| PE Ratio | 47.80 |
| Forward PE | 36.51 |
| PS Ratio | 6.11 |
| PB Ratio | 5.48 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 50.68 |
| EV / Sales | 6.48 |
| EV / EBITDA | 27.70 |
| EV / EBIT | 36.10 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.54 |
| Debt / EBITDA | 2.58 |
| Debt / FCF | n/a |
| Interest Coverage | 3.66 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 10.07% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 7.09M |
| Profits Per Employee | 906,906 |
| Employee Count | 19,620 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Mankind Pharma has paid 3.81 billion in taxes.
| Income Tax | 3.81B |
| Effective Tax Rate | 17.42% |
Stock Price Statistics
The stock price has decreased by -14.91% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -14.91% |
| 50-Day Moving Average | 2,153.40 |
| 200-Day Moving Average | 2,375.57 |
| Relative Strength Index (RSI) | 41.88 |
| Average Volume (20 Days) | 22,091 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mankind Pharma had revenue of INR 139.14 billion and earned 17.79 billion in profits. Earnings per share was 43.10.
| Revenue | 139.14B |
| Gross Profit | 97.74B |
| Operating Income | 24.87B |
| Pretax Income | 21.89B |
| Net Income | 17.79B |
| EBITDA | 32.33B |
| EBIT | 24.87B |
| Earnings Per Share (EPS) | 43.10 |
Balance Sheet
The company has 34.99 billion in cash and 83.69 billion in debt, with a net cash position of -48.70 billion.
| Cash & Cash Equivalents | 34.99B |
| Total Debt | 83.69B |
| Net Cash | -48.70B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 155.29B |
| Book Value Per Share | 370.26 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 70.25%, with operating and profit margins of 17.87% and 12.79%.
| Gross Margin | 70.25% |
| Operating Margin | 17.87% |
| Pretax Margin | 15.73% |
| Profit Margin | 12.79% |
| EBITDA Margin | 23.24% |
| EBIT Margin | 17.87% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 0.05%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 0.05% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -2.76% |
| Shareholder Yield | -2.71% |
| Earnings Yield | 2.09% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |